Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer

Clinical trial NCT04659382 · UNKNOWN

Trial details

NCT number: NCT04659382
Sponsor: Federation Francophone de Cancerologie Digestive
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Colorectal Cancer pMMR MSS Immune Checkpoint Inhibitor Internal Radiotherapy

Start date: 2020-10-07
Primary completion: 2024-10-31
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.